ANGELES ALVAREZ RIBELLES-rekin lankidetzan egindako argitalpenak (9)

2024

  1. Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction

    Antiviral Research, Vol. 231

2022

  1. Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz

    Biomedicines, Vol. 10, Núm. 1

2020

  1. Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis

    Journal of Investigative Dermatology, Vol. 140, Núm. 11, pp. 2294-2298.e6

2018

  1. Abacavir induces arterial thrombosis in a murine model

    Journal of Infectious Diseases

2015

  1. Differential effects of anti-TNF-α and anti-IL-12/23 agents on human leukocyte-endothelial cell interactions

    European Journal of Pharmacology, Vol. 765, pp. 355-365

  2. Efavirenz and the CNS: What we already know and questions that need to be answered

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 10, pp. 2693-2708

2014

  1. Neuronal bioenergetics and acute mitochondrial dysfunction: A clue to understanding the central nervous system side effects of efavirenz

    Journal of Infectious Diseases, Vol. 210, Núm. 9, pp. 1385-1395

2010

  1. Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells

    British Journal of Pharmacology, Vol. 160, Núm. 8, pp. 2069-2084

2007

  1. Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors

    Journal of Pharmacology and Experimental Therapeutics, Vol. 323, Núm. 1, pp. 406-413